Develop business Strategies Of Acute Myeloid Leukemia Market 2024

"The Latest Research Report OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2024 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

About Acute Myeloid Leukemia Market

Acute myeloid (myelogenous, myelocytic) leukemia (AML) is a rapidly progressing blood cancer with an extremely poor overall prognosis. AML predominantly affects the elderly population and this subgroup of patients has an exceptionally high level of unmet needs. GlobalData estimates the 2014 sales for AML at approximately $342 million across the 7MM covered in this report. The market will increase by almost three-fold over the forecast period, reaching $932 million in 2024 at a CAGR of 10.5%. This growth will be driven by an increase in incident cases of AML as well as the approval and uptake of premium-priced products, such as FLT3 kinase inhibitors (quizartinib and midostaurin), a PI3 kinase inhibitor (volasertib) and new formulations of existing chemotherapies such as Vyxeos (CPX-351), guadecitabine and CC-486. GlobalData expects, by the end of the forecast period, new branded therapies Vyxeos, volasertib and CC-486 will dominate the market along with generic azacitidine. The AML pipeline is weak in terms of efficacy; however, GlobalData expects none of these drugs to have a major impact on the overall AML market. The challenge for new entrants into the AML market is to meet the critically high unmet needs of AML patients and improve overall survival. One of the opportunities for the companies is to work cooperatively to develop therapies that work in combination with chemotherapy backbone.

Highlights

Key Questions Answered

- For over forty years, there has been no major advances in the treatment for AML. The AML space is filled with excitement because the first targeted FLT3 kinase inhibitor therapies are expected to change the treatment landscape. What will be the impact of these newly approved drugs on AML sales?
- With the unmet needs of AML patients remaining critically high, what R&D strategies and opportunities are being used by drug makers to remain competitive?

Get Sample Copy Of This Report @ https://www.marketresearchreports.biz/sample/sample/631642

- The survival of patients with AML remains dismal, especially for those who do not respond to first-line chemotherapies. Therefore, there are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the AML market?

Key Findings

- One of the main drivers in the expansion of the AML market will be the launch of premium-priced targeted therapies (FLT3 kinase inhibitors, PI3 kinase inhibitor and reformulations of chemotherapy drugs). for patients with extremely high unmet needs, both the elderly and refractory/relapsed population. These drugs will gradually be used in combination with or replace cheaper, generic, cytarabine-based chemotherapy regimens.
- Another driver will be the few players in the AML market, and that current therapies are largely considered to be ineffective. Therefore, there is ample room for new market entrants. A major driver will also be that a growing incident elderly AML population, particularly in the US, will increase the number of treatable AML patients.
- Companies are focusing on the development of combination therapies, trying to improve the complete remission rate and duration of remission.
- One of the largest unmet needs is a need for efficacious treatment options for elderly AML patients. The majority of AML patients do not have FLT3 mutations, and are therefore ineligible for FLT3 inhibitor treatments. Other unmet needs include therapies for refractory/relapsed disease.

View Report @ https://www.marketresearchreports.biz/reports/631642/opportunityanalyzer-acute-myeloid-leukemia-aml-opportunity-analysis-and-forecasts-to-2024-market-research-reports

Scope

- Overview of AML, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized AML therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in four patient segments (including, young patients, elderly patients, refractory/relapsed patients and FLT3 mutated patients), forecast from 2014 to 2024.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AML therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for different lines of therapy. The most promising candidate in Phase III development is profiled.
- Analysis of the current and future market competition in the global AML therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global AML therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global melanoma therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Send An Enquiry Request @ https://www.marketresearchreports.biz/sample/enquiry/631642

Table of Contents

1 Table of Contents 10
1.1 List of Tables 15
1.2 List of Figures 21
2 Introduction 23
2.1 Catalyst 23
2.2 Related Reports 23
2.3 Upcoming Related Reports 23
3 Disease Overview 24
3.1 Etiology and Pathophysiology 24
3.1.1 Pathophysiology 25
3.1.2 Classification 26
3.1.3 Cytogenetic and Molecular Abnormalities 29
3.2 Prognosis 35
3.3 Quality of Life 36
3.4 Symptoms 37
4 Epidemiology 39
4.1 Disease Background 39
4.2 Risk Factors and Comorbidities 40
4.2.1 Increased age is associated with increased risk and worsened prognosis 41
4.2.2 Smoking increases the risk of M2 AML 42
4.2.3 APL is relatively common among Spanish and Italian origins 42
4.2.4 Chemotherapy and radiation therapy increases the risk of AML 43
4.2.5 Benzene increases risk of AML 43
4.3 Global Trends 44
4.3.1 Incidence 44
4.3.2 Survival and Prevalence 46
4.3.3 Subtypes and Mutations 47
4.3.4 Risk Groups 49
4.4 Forecast Methodology 52
4.4.1 Sources Used 53
4.4.2 Forecast Assumptions and Methods 60
4.4.3 Sources not Used 66
4.5 Epidemiological Forecast for Acute Myeloid Leukemia (2014-2024) 67
4.5.1 Adjusted Diagnosed Incident Cases of AML 67
4.5.2 Adjusted Diagnosed Incident Cases of AML by Age 69
4.5.3 Adjusted Diagnosed Incident Cases of AML by Sex 70
4.5.4 Age-Standardized Incidence of AML 72
4.5.5 APL and MDS/tAML 73
4.5.6 APL and MDS/tAML by Age 76
4.5.7 Diagnosed Incident Cases of AML with FLT3 Mutations 78
4.5.8 Diagnosed Incident Cases of AML by Risk Group Classifications 79
4.5.9 Five-Year Diagnosed Prevalent Cases of AML 83
4.5.10 Five-Year Diagnosed Prevalent Cases of AML by Age 84
4.5.11 Five-Year Diagnosed Prevalent Cases of APL and MDS/tAML 85
4.5.12 Five-Year Diagnosed Prevalent Cases of APL and MDS/tAML by Age 87
4.6 Discussion 88
4.6.1 Epidemiological Forecast Insight 88
4.6.2 Limitations of the Analysis 89
4.6.3 Strengths of the Analysis 90
5 Disease Management 91
5.1 Treatment Overview 91
5.2 Response Criteria and Outcome Measures 93
5.3 General Treatment Overview 95
5.3.1 Younger AML Patients 97
5.3.2 Older AML Patients 99
5.4 Hematopoietic Stem Cell Transplant 102
5.5 Monitoring for Residual Disease 104
5.6 Acute Promyelocytic Leukemia 104
6 Current Treatment Options 107
6.1 Overview 107
6.2 Product Profiles - Major Brands 110
6.2.1 Cytarabine 110
6.2.2 Dacogen (decitabine) 114
6.2.3 Vidaza (azacitidine) 120
6.2.4 Mylotarg (gemtuzumab ozogamicin) 128
6.2.5 Other Therapeutic Agents for AML 135

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

This release was published on openPR.